Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Timed kil curves

Published byAmie Booker Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Timed kil curves"— Presentation transcript:

1 Figure 1 Timed kil curves
Figure 1 Timed kil curves. A, tPMP-1—susceptible strain ISP479C against vancomycin. B, tPMP-1—resistant strain ISP479R against vancomycin. Solid lines, growth control in Mueler-Hinton broth (MHB); dashed lines, vancomycin-containing media. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

2 Table 1 Influence of vancomycin therapy on vegetation densities (mean ± SD of log<sub>10</sub> cfu/g) in rabbits with experimental endocarditis caused by either tPMP-1—susceptible (ISP479C) or tPMP-1—resistant strain of S. aureus. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

3 Table 3 Influence of vancomycin therapy on splenic abscess bacterial densities (mean ± SD of log<sub>10</sub> cfu/g) in rabbits with experimental endocarditis caused by either tPMP-1—susceptible (ISP479C) or tPMP-1—resistant strain of Staphylococcus aureus. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

4 Table 4 Results of vancomycin prophylaxis of experimental endocarditis when catheterized rabbits were challenged by either tPMP-1—susceptible (ISP479C) or tPMP-1—resistant (ISP479R) strain of S. aureus. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

5 Figure 2 Effect of vancomycin preexposure on subsequent tPMP-1—induced killing of tPMP-1—susceptible strain ISP479C over range of peptide concentrations (0.004–2.5 µg/mL). Open bars, killing by tPMP-1 alone (no vancomycin preexposure); closed bars, killing by tPMP-1 after 1-h pre-exposure to vancomycin. Bars are mean log<sub>10</sub> cfu/mL of 3 independent runs. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

6 Figure 3 Effect of vancomycin preexposure on subsequent tPMP-1—induced killing of tPMP-1—resistant strain ISP479R over range of peptide concentrations (0.004–2.5 µg/mL). Open bars, killing by tPMP-1 alone (no vancomycin preexposure); closed bars, killing by tPMP-1 after 1-h pre-exposure to vancomycin. Bars are mean log<sub>10</sub> cfu/mL of 3 independent runs. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

7 Figure 5 Bactericidal effects of combinations of sublethal vancomycin (0.5 × minimum inhibitory concentration) + range of sublethal tPMP-1 concentrations (0–1.25 µg/mL) against tPMP-1—resistant strain ISP479R. Bars are mean log<sub>10</sub> cfu/mL of 3 independent runs. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

8 Figure 4 Bactericidal effects of combinations of sublethal vancomycin (0.5 × minimum inhibitory concentration) + range of sublethal tPMP-1 concentrations (0–1.25 µg/mL) against tPMP-1—susceptible strain ISP479C. Bars are mean log<sub>10</sub> cfu/mL of 3 independent runs. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

9 Table 2 Influence of vancomycin therapy on renal abscess bacterial densities (mean ± SD of log<sub>10</sub> cfu/g) in rabbits with experimental endocarditis caused by either tPMP-1—susceptible (ISP479C) or tPMP-1—resistant strain of S. aureus. From: Influence of In Vitro Susceptibility Phenotype against Thrombin-Induced Platelet Microbicidal Protein on Treatment and Prophylaxis Outcomes of Experimental Staphylococcus aureus Endocarditis J Infect Dis. 1999;180(5): doi: /315063 J Infect Dis | © 1999 by the Infectious Diseases Society of America

Download ppt "Figure 1 Timed kil curves"

Similar presentations

Relationship between Time to Eradication in vivo & Bactericidal Activity in vitro of Vancomycin for MRSA Infections Pamela A. Moise-Broder Alan Forrest.

Relationship between Time to Eradication in vivo & Bactericidal Activity in vitro of Vancomycin for MRSA Infections Pamela A. Moise-Broder Alan Forrest.
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.
Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.
Clinical Microbiology and Infection

Clinical Microbiology and Infection
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Targeting Multidrug-resistant Staphylococci with an anti-rpoA Peptide Nucleic Acid Conjugated to the HIV-1 TAT Cell Penetrating Peptide  Mostafa FN Abushahba,

Targeting Multidrug-resistant Staphylococci with an anti-rpoA Peptide Nucleic Acid Conjugated to the HIV-1 TAT Cell Penetrating Peptide  Mostafa FN Abushahba,
Figure 1. Blue light inactivation of Acinetobacter baumannii and keratinocytes in vitro. Bars denote SDs. From: Antimicrobial Blue Light Therapy for Multidrug-Resistant.

Figure 1. Blue light inactivation of Acinetobacter baumannii and keratinocytes in vitro. Bars denote SDs. From: Antimicrobial Blue Light Therapy for Multidrug-Resistant.
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Antimicrobial Susceptibility Testing (AST)

Antimicrobial Susceptibility Testing (AST)
From: Rotarix: A Rotavirus Vaccine for the World

From: Rotarix: A Rotavirus Vaccine for the World
From: Postinfectious Irritable Bowel Syndrome

From: Postinfectious Irritable Bowel Syndrome
Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.
In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria  Matthew W. Ruble, Deborah H. Gilbert, Stephen.

In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria  Matthew W. Ruble, Deborah H. Gilbert, Stephen.
F1-3999 48th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, 2008. Washington, DC The Activity of RTA-3, a Novel Antimicrobial.

F th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC The Activity of RTA-3, a Novel Antimicrobial.
Clinical Microbiology and Infection

Clinical Microbiology and Infection
M.A.C. Broeren, Y. Maas, E. Retera, N.L.A. Arents 

M.A.C. Broeren, Y. Maas, E. Retera, N.L.A. Arents 
Approach to diagnosis of infective endocarditis

Approach to diagnosis of infective endocarditis
Incidence and outcome of Staphylococcus aureus endocarditis—a 10-year single-centre northern European experience  H. Asgeirsson, A. Thalme, M. Kristjansson,

Incidence and outcome of Staphylococcus aureus endocarditis—a 10-year single-centre northern European experience  H. Asgeirsson, A. Thalme, M. Kristjansson,
Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients 

Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients 

Similar presentations

Ads by Google